---
figid: PMC7175141__biomolecules-10-00358-g001
figtitle: Association between IDH1/2 mutation and NAD Production in Cancer
organisms:
- NA
pmcid: PMC7175141
filename: biomolecules-10-00358-g001.jpg
figlink: pmc/articles/PMC7175141/figure/biomolecules-10-00358-f001/
number: F1
caption: 'The association between IDH1/2 mutation and NAD Production in Cancer. Mutant
  IDH1/2 converts α-ketoglutarate (α-KG) into D-2 hydroxyglutarate (D-2HG), an oncometabolite
  that causes hypermethylation at CpG islands of NAPRT promoter region, results in
  nicotinic acid pathway inhibition. Cancer cells maintain the adequate level of NAD
  pool through NAD salvage pathway and NADPH generation. NADPH is used as a substrate
  to generate D-2HG to promote oncogenesis. One of the possible mechanisms for cancer
  cell survival is achieved through catalytic activity of dihydrofolate reductase
  (DHFR) that maintains folate pool and induces DNA synthesis. TCA: tricarboxylic
  acid; NAPRT: nicotinate phosphoribosyltransferase; NAMN: nicotinic acid mononucleotide;
  NAAD: nicotinic acid adenine dinucleotide; NADS: NAD synthase; QAPRT: quinolinate
  phosphoribosyltransferase; NMN: nicotinamide mononucleotide; NAR: nicotinic acid
  riboside; NR: nicotinamide riboside; NRK1/2: nicotinamide riboside kinase 1/2; H2F:
  dihydrofolate; H4F: tetrahydrofolate.'
papertitle: 'NAD- and NADPH-Contributing Enzymes as Therapeutic Targets in Cancer:
  An Overview.'
reftext: Alvinsyah Adhityo Pramono, et al. Biomolecules. 2020 Mar;10(3):358.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.8964777
figid_alias: PMC7175141__F1
figtype: Figure
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
redirect_from: /figures/PMC7175141__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7175141__biomolecules-10-00358-g001.html
  '@type': Dataset
  description: 'The association between IDH1/2 mutation and NAD Production in Cancer.
    Mutant IDH1/2 converts α-ketoglutarate (α-KG) into D-2 hydroxyglutarate (D-2HG),
    an oncometabolite that causes hypermethylation at CpG islands of NAPRT promoter
    region, results in nicotinic acid pathway inhibition. Cancer cells maintain the
    adequate level of NAD pool through NAD salvage pathway and NADPH generation. NADPH
    is used as a substrate to generate D-2HG to promote oncogenesis. One of the possible
    mechanisms for cancer cell survival is achieved through catalytic activity of
    dihydrofolate reductase (DHFR) that maintains folate pool and induces DNA synthesis.
    TCA: tricarboxylic acid; NAPRT: nicotinate phosphoribosyltransferase; NAMN: nicotinic
    acid mononucleotide; NAAD: nicotinic acid adenine dinucleotide; NADS: NAD synthase;
    QAPRT: quinolinate phosphoribosyltransferase; NMN: nicotinamide mononucleotide;
    NAR: nicotinic acid riboside; NR: nicotinamide riboside; NRK1/2: nicotinamide
    riboside kinase 1/2; H2F: dihydrofolate; H4F: tetrahydrofolate.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ca
  - Naprt
  - CycE
  - cyc
  - Kg
  - Nmnat
  - Nadsyn
  - de
  - NADK
  - CG33156
  - Dhfr
  - Hf
  - nr
  - NAPRT
  - CPSF4
  - NMRK1
  - NEK4
  - NMRK2
  - NMNAT1
  - DECR1
  - DHFR
  - BST1
  - NAMPT
---
